Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Ectopic pregnancy and outcomes of future intrauterine pregnancy.

Chouinard M, Mayrand MH, Ayoub A, Healy-Profitós J, Auger N.

Fertil Steril. 2019 May 2. pii: S0015-0282(19)30292-4. doi: 10.1016/j.fertnstert.2019.03.019. [Epub ahead of print]

PMID:
31056305
2.

Assessing the time dependence of prognostic values of cytology and human papillomavirus testing in cervical cancer screening.

Isidean SD, Wang Y, Mayrand MH, Ratnam S, Coutlée F, Franco EL, Abrahamowicz M; CCCaST Study Group.

Int J Cancer. 2019 May 15;144(10):2408-2418. doi: 10.1002/ijc.31970. Epub 2019 Jan 21.

PMID:
30411802
3.

Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated, HPV-negative women: a modelling study.

Malagón T, Kulasingam S, Mayrand MH, Ogilvie G, Smith L, Bouchard C, Gotlieb W, Franco EL.

Lancet Oncol. 2018 Dec;19(12):1569-1578. doi: 10.1016/S1470-2045(18)30536-9. Epub 2018 Nov 1. Erratum in: Lancet Oncol. 2019 Jan;20(1):e10.

PMID:
30392810
4.

Pelvic Floor Muscle Morphometry and Function in Women With Primary and Secondary Provoked Vestibulodynia.

Fontaine F, Dumoulin C, Bergeron S, Mayrand MH, Khalifé S, Wadell G, Morin M.

J Sex Med. 2018 Aug;15(8):1149-1157. doi: 10.1016/j.jsxm.2018.06.001. Epub 2018 Jul 20.

PMID:
30033191
5.

Impact of Acetic Acid on HPV Testing Using Hybrid Capture 2.

Pina A, Sauthier P, Coutlée F, Trottier H, Mayrand MH.

J Low Genit Tract Dis. 2018 Oct;22(4):352-354. doi: 10.1097/LGT.0000000000000409.

PMID:
29957658
6.

Cervical cancer screening in Montreal: Building evidence to support primary care and policy interventions.

Datta GD, Blair A, Sylvestre MP, Gauvin L, Drouin M, Mayrand MH.

Prev Med. 2018 Jun;111:265-271. doi: 10.1016/j.ypmed.2018.02.037. Epub 2018 Mar 8.

7.

Daily Anxiety and Depressive Symptoms in Couples Coping With Vulvodynia: Associations With Women's Pain, Women's Sexual Function, and Both Partners' Sexual Distress.

Pâquet M, Rosen NO, Steben M, Mayrand MH, Santerre-Baillargeon M, Bergeron S.

J Pain. 2018 May;19(5):552-561. doi: 10.1016/j.jpain.2017.12.264. Epub 2018 Jan 5.

PMID:
29309891
8.

Group physiotherapy compared to individual physiotherapy to treat urinary incontinence in aging women: study protocol for a randomized controlled trial.

Dumoulin C, Morin M, Mayrand MH, Tousignant M, Abrahamowicz M.

Trials. 2017 Nov 16;18(1):544. doi: 10.1186/s13063-017-2261-4.

9.

Human papillomavirus (HPV) perinatal transmission and risk of HPV persistence among children: Design, methods and preliminary results of the HERITAGE study.

Trottier H, Mayrand MH, Coutlée F, Monnier P, Laporte L, Niyibizi J, Carceller AM, Fraser WD, Brassard P, Lacroix J, Francoeur D, Bédard MJ, Girard I, Audibert F.

Papillomavirus Res. 2016 Dec;2:145-152. doi: 10.1016/j.pvr.2016.07.001. Epub 2016 Jul 12.

10.

The EVVA Cohort Study: Anal and Cervical Type-Specific Human Papillomavirus Prevalence, Persistence, and Cytologic Findings in Women Living With HIV.

de Pokomandy A, Kaufman E, de Castro C, Mayrand MH, Burchell AN, Klein M, Charest L, Auger M, Rodrigues-Coutlée S, Coutlée F; EVVA Study Group.

J Infect Dis. 2017 Aug 15;216(4):447-456. doi: 10.1093/infdis/jix273.

PMID:
28931234
11.

Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.

Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, Bartholomew D, Cestero RM, Fedrizzi EN, Hirschberg AL, Mayrand MH, Ruiz-Sternberg AM, Stapleton JT, Wiley DJ, Ferenczy A, Kurman R, Ronnett BM, Stoler MH, Cuzick J, Garland SM, Kjaer SK, Bautista OM, Haupt R, Moeller E, Ritter M, Roberts CC, Shields C, Luxembourg A.

Lancet. 2017 Nov 11;390(10108):2143-2159. doi: 10.1016/S0140-6736(17)31821-4. Epub 2017 Sep 5.

PMID:
28886907
12.

The association between adverse pregnancy outcomes and maternal human papillomavirus infection: a systematic review protocol.

Niyibizi J, Zanré N, Mayrand MH, Trottier H.

Syst Rev. 2017 Mar 11;6(1):53. doi: 10.1186/s13643-017-0443-5.

13.

Introduction of molecular HPV testing as the primary technology in cervical cancer screening: Acting on evidence to change the current paradigm.

Tota JE, Bentley J, Blake J, Coutlée F, Duggan MA, Ferenczy A, Franco EL, Fung-Kee-Fung M, Gotlieb W, Mayrand MH, McLachlin M, Murphy J, Ogilvie G, Ratnam S.

Prev Med. 2017 May;98:5-14. doi: 10.1016/j.ypmed.2016.11.029. Epub 2017 Feb 6.

PMID:
28279264
14.

Approaches for triaging women who test positive for human papillomavirus in cervical cancer screening.

Tota JE, Bentley J, Blake J, Coutlée F, Duggan MA, Ferenczy A, Franco EL, Fung-Kee-Fung M, Gotlieb W, Mayrand MH, McLachlin M, Murphy J, Ogilvie G, Ratnam S.

Prev Med. 2017 May;98:15-20. doi: 10.1016/j.ypmed.2016.11.030. Epub 2017 Feb 6.

PMID:
28279257
15.

Comparison of Triage Strategies for HPV-Positive Women: Canadian Cervical Cancer Screening Trial Results.

Isidean SD, Mayrand MH, Ramanakumar AV, Rodrigues I, Ferenczy A, Ratnam S, Coutlée F, Franco EL; CCCaST Study Group.

Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):923-929. doi: 10.1158/1055-9965.EPI-16-0705. Epub 2017 Jan 17.

16.

Epidemiologic Evaluation of Human Papillomavirus Type Competition and the Potential for Type Replacement Post-Vaccination.

Tota JE, Jiang M, Ramanakumar AV, Walter SD, Kaufman JS, Coutlée F, Richardson H, Burchell AN, Koushik A, Mayrand MH, Villa LL, Franco EL.

PLoS One. 2016 Dec 22;11(12):e0166329. doi: 10.1371/journal.pone.0166329. eCollection 2016.

17.

Human papillomavirus testing versus cytology in primary cervical cancer screening: End-of-study and extended follow-up results from the Canadian cervical cancer screening trial.

Isidean SD, Mayrand MH, Ramanakumar AV, Gilbert L, Reid SL, Rodrigues I, Ferenczy A, Ratnam S, Coutlée F, Franco EL; CCCaST Study Group.

Int J Cancer. 2016 Dec 1;139(11):2456-66. doi: 10.1002/ijc.30385. Epub 2016 Aug 30.

18.

Observed and Perceived Disclosure and Empathy Are Associated With Better Relationship Adjustment and Quality of Life in Couples Coping With Vulvodynia.

Rosen NO, Bois K, Mayrand MH, Vannier S, Bergeron S.

Arch Sex Behav. 2016 Nov;45(8):1945-1956. Epub 2016 May 10.

PMID:
27164894
19.

Atypical glandular cells on cervical cytology.

Mayrand MH, Koushik A.

BMJ. 2016 Feb 11;352:i723. doi: 10.1136/bmj.i723. No abstract available.

PMID:
26869616
20.

Why Us? Perceived Injustice is Associated With More Sexual and Psychological Distress in Couples Coping With Genito-Pelvic Pain.

Pâquet M, Bois K, Rosen NO, Mayrand MH, Charbonneau-Lefebvre V, Bergeron S.

J Sex Med. 2016 Jan;13(1):79-87. doi: 10.1016/j.jsxm.2015.11.007.

PMID:
26755090
21.

Intimacy, sexual satisfaction, and sexual distress in vulvodynia couples: An observational study.

Bois K, Bergeron S, Rosen N, Mayrand MH, Brassard A, Sadikaj G.

Health Psychol. 2016 Jun;35(6):531-540. doi: 10.1037/hea0000289. Epub 2015 Dec 21.

PMID:
26690636
22.
23.

Randomized clinical trial of multimodal physiotherapy treatment compared to overnight lidocaine ointment in women with provoked vestibulodynia: Design and methods.

Morin M, Dumoulin C, Bergeron S, Mayrand MH, Khalifé S, Waddell G, Dubois MF; Provoked vestibulodynia (PVD) Study Group.

Contemp Clin Trials. 2016 Jan;46:52-59. doi: 10.1016/j.cct.2015.11.013. Epub 2015 Nov 18.

PMID:
26600287
24.

Risk of Human Papillomavirus (HPV) Infection and Cervical Neoplasia after Pregnancy.

Trottier H, Mayrand MH, Baggio ML, Galan L, Ferenczy A, Villa LL, Franco EL; Ludwig-McGill Cohort Study Group.

BMC Pregnancy Childbirth. 2015 Oct 7;15:244. doi: 10.1186/s12884-015-0675-0.

25.

A comparison of cognitive-behavioral couple therapy and lidocaine in the treatment of provoked vestibulodynia: study protocol for a randomized clinical trial.

Corsini-Munt S, Bergeron S, Rosen NO, Steben M, Mayrand MH, Delisle I, McDuff P, Aerts L, Santerre-Baillargeon M.

Trials. 2014 Dec 23;15:506. doi: 10.1186/1745-6215-15-506.

26.

Evaluation of human papillomavirus type replacement postvaccination must account for diagnostic artifacts: masking of HPV52 by HPV16 in anogenital specimens.

Tota JE, Ramanakumar AV, Villa LL, Richardson H, Burchell AN, Koushik A, Mayrand MH, Coutlée F, Franco EL.

Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):286-90. doi: 10.1158/1055-9965.EPI-14-0566. Epub 2014 Oct 2.

27.

Feasibility and preliminary effectiveness of a novel cognitive-behavioral couple therapy for provoked vestibulodynia: a pilot study.

Corsini-Munt S, Bergeron S, Rosen NO, Mayrand MH, Delisle I.

J Sex Med. 2014 Oct;11(10):2515-27. doi: 10.1111/jsm.12646. Epub 2014 Jul 24.

PMID:
25059263
28.

Prevalence of human papillomaviruses in semen: a systematic review and meta-analysis.

Laprise C, Trottier H, Monnier P, Coutlée F, Mayrand MH.

Hum Reprod. 2014 Apr;29(4):640-51. doi: 10.1093/humrep/det453. Epub 2013 Dec 22. Review.

PMID:
24365799
29.

Morphometry of the pelvic floor muscles in women with and without provoked vestibulodynia using 4D ultrasound.

Morin M, Bergeron S, Khalifé S, Mayrand MH, Binik YM.

J Sex Med. 2014 Mar;11(3):776-85. doi: 10.1111/jsm.12367. Epub 2013 Nov 6.

PMID:
24344835
30.

Response.

Brisson M, Drolet M, Boily MC, Malagón T, Franco EL, Laprise J, Van de Velde N, Mayrand MH, Kliewer EV, Coutlée F.

J Natl Cancer Inst. 2013 May 1;105(9):664-5. No abstract available.

PMID:
23767055
31.

Juvenile respiratory papillomatosis: risk factors for severity.

Rodier C, Lapointe A, Coutlée F, Mayrand MH, Dal Soglio D, Roger M, Trottier H.

J Med Virol. 2013 Aug;85(8):1447-58. doi: 10.1002/jmv.23615.

PMID:
23765781
32.

Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.

Van de Velde N, Boily MC, Drolet M, Franco EL, Mayrand MH, Kliewer EV, Coutlée F, Laprise JF, Malagón T, Brisson M.

J Natl Cancer Inst. 2012 Nov 21;104(22):1712-23. doi: 10.1093/jnci/djs395. Epub 2012 Oct 27.

PMID:
23104323
33.

Determinants of lymph node count in endometrial cancer surgical staging.

Cormier B, Sauthier P, Lussier C, Zang G, Mayrand MH.

Int J Gynecol Cancer. 2012 Oct;22(8):1361-6.

PMID:
22964526
34.

Early versus late amniotomy for labour induction: a randomized controlled trial.

Gagnon-Gervais K, Bujold E, Iglesias MH, Duperron L, Masse A, Mayrand MH, Sansregret A, Fraser W, Audibert F.

J Matern Fetal Neonatal Med. 2012 Nov;25(11):2326-9. doi: 10.3109/14767058.2012.695819. Epub 2012 Jun 13.

PMID:
22616980
35.

Human papillomavirus (HPV) DNA triage of women with atypical squamous cells of undetermined significance with cobas 4800 HPV and Hybrid Capture 2 tests for detection of high-grade lesions of the uterine cervix.

Lapierre SG, Sauthier P, Mayrand MH, Dufresne S, Petignat P, Provencher D, Drouin P, Gauthier P, Dupuis MJ, Michon B, Ouellet S, Hadjeres R, Ferenczy A, Franco EL, Coutlée F.

J Clin Microbiol. 2012 Apr;50(4):1240-4. doi: 10.1128/JCM.06656-11. Epub 2012 Feb 1.

36.

Generic microtiter plate assay for triaging clinical specimens prior to genotyping of human papillomavirus DNA via consensus PCR.

Legault V, Burchell A, Goggin P, Nicolau B, Brassard P, Guenoun J, Forest P, Mayrand MH, Franco EL, Coutlée F.

J Clin Microbiol. 2011 Nov;49(11):3977-9. doi: 10.1128/JCM.05646-11. Epub 2011 Sep 21.

37.

[Obstetricians/gynaecologists and breastfeeding: practice, attitudes, training and knowledge].

Simard-Émond L, Sansregret A, Dubé J, Mayrand MH.

J Obstet Gynaecol Can. 2011 Feb;33(2):145-52. French.

PMID:
21352634
38.

Integrating novel primary- and secondary-prevention strategies: the next challenge for cervical cancer control.

Mayrand MH, Franco EL.

Future Oncol. 2010 Nov;6(11):1725-33. doi: 10.2217/fon.10.141.

PMID:
21142659
39.

Human papillomavirus (HPV) DNA triage of women with atypical squamous cells of undetermined significance with Amplicor HPV and Hybrid Capture 2 assays for detection of high-grade lesions of the uterine cervix.

Dufresne S, Sauthier P, Mayrand MH, Petignat P, Provencher D, Drouin P, Gauthier P, Dupuis MJ, Michon B, Ouellet S, Hadjeres R, Ferenczy A, Franco EL, Coutlée F.

J Clin Microbiol. 2011 Jan;49(1):48-53. doi: 10.1128/JCM.01063-10. Epub 2010 Nov 17.

40.

Cost-effectiveness of high-risk human papillomavirus testing for cervical cancer screening in Québec, Canada.

Vijayaraghavan A, Efrusy MB, Mayrand MH, Santas CC, Goggin P.

Can J Public Health. 2010 May-Jun;101(3):220-5.

PMID:
20737813
41.

Second-look targeted studies after breast magnetic resonance imaging: practical tips to improve lesion identification.

Trop I, Labelle M, David J, Mayrand MH, Lalonde L.

Curr Probl Diagn Radiol. 2010 Sep-Oct;39(5):200-11. doi: 10.1067/j.cpradiol.2009.07.006. Review.

PMID:
20674767
42.

Multimodality breast cancer screening in women with a familial or genetic predisposition.

Trop I, Lalonde L, Mayrand MH, David J, Larouche N, Provencher D.

Curr Oncol. 2010 Jun;17(3):28-36.

43.

The impact of intolerance of uncertainty on anxiety after receiving an informational intervention about HPV: a randomised controlled study.

Rosen NO, Knäuper B, Di Dio P, Morrison E, Tabing R, Feldstain A, Amsel R, Mayrand MH, Franco EL, Rosberger Z.

Psychol Health. 2010 Jul;25(6):651-68. doi: 10.1080/08870440902822913.

PMID:
20204959
44.

Brief research report: uncertainty-inducing and reassuring facts about HPV: a descriptive study of French Canadian women.

Rosen NO, Knäuper B, Pagé G, Di Dio P, Morrison E, Mayrand MH, Franco EL, Rosberger Z.

Health Care Women Int. 2009 Oct;30(10):892-902. doi: 10.1080/07399330903066434.

PMID:
19742363
45.

Detection and typing of human papillomavirus nucleic acids in biological fluids.

Coutlée F, Mayrand MH, Roger M, Franco EL.

Public Health Genomics. 2009;12(5-6):308-18. doi: 10.1159/000214921. Epub 2009 Aug 11. Review.

PMID:
19684443
46.

Experiences and decisions that motivate women at increased risk of breast cancer to participate in an experimental screening program.

Proulx M, Beaulieu MD, Loignon C, Mayrand MH, Maugard C, Bellavance N, Provencher D.

J Genet Couns. 2009 Apr;18(2):160-72. doi: 10.1007/s10897-008-9202-z. Epub 2009 Feb 14.

PMID:
19219540
47.

Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.

Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, Dillner J, Meijer CJ.

Vaccine. 2008 Aug 19;26 Suppl 10:K29-41. doi: 10.1016/j.vaccine.2008.06.019. Review.

PMID:
18847555
48.

Amniocentesis for PPROM management: a feasibility study.

Lacerte M, Bujold E, Audibert F, Mayrand MH.

J Obstet Gynaecol Can. 2008 Aug;30(8):659-664. doi: 10.1016/S1701-2163(16)32913-9.

PMID:
18786287
49.

Vaccination against human papillomavirus.

Franco EL, de Pokomandy A, Spence AR, Burchell AN, Trottier H, Mayrand MH, Lau S.

CMAJ. 2007 Dec 4;177(12):1524-5; author reply 1527-8. No abstract available.

50.

Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.

Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlée F, Franco EL; Canadian Cervical Cancer Screening Trial Study Group.

N Engl J Med. 2007 Oct 18;357(16):1579-88.

Supplemental Content

Loading ...
Support Center